Compare AbbVie Inc (ABBV) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs JPMorgan Ultra Short Income ETF — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while JPMorgan Ultra Short Income ETF trades at $50.44. The key difference: AbbVie Inc pays a 2.72% dividend while JPMorgan Ultra Short Income ETF pays none, and AbbVie Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | JPST | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $261.07 | $50.78 |
52-Week Low | $184.85 | $50.40 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.45, up 0.06% on the day. The technical outlook is bearish based on moving averages, with oscillators neutral. Recent news highlights its role as a cash alternative, with institutional inflows and consistent monthly dividends. The fund focuses on high-quality, short-term bonds for income and capital preservation.
The outlook remains stable given its low-risk profile, offering a yield advantage over savings accounts. Risks include interest rate sensitivity and credit spread changes. Wall Street sentiment is positive for risk-averse investors seeking short-term income, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
